Cargando…
Early detection of treatment futility in patients with metastatic colorectal cancer
Purpose: Chemotherapy options for treating CRC have rapidly expanded in recent years, and few have predictive biomarkers. Oncologists are challenged with evidence-based selection of treatments, and response is evaluated retrospectively based on serial imaging beginning after 2–3 months. As a result,...
Autores principales: | Rattner, Jodi I., Kopciuk, Karen A., Vogel, Hans J., Tang, Patricia A., Shapiro, Jeremy D., Tu, Dongsheng, Jonker, Derek J., Siu, Lillian L., O’Callaghan, Chris J., Bathe, Oliver F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8746015/ https://www.ncbi.nlm.nih.gov/pubmed/35028011 http://dx.doi.org/10.18632/oncotarget.28165 |
Ejemplares similares
-
Clinical and metabolomic characterization of Brivanib‐Induced hypertension in metastatic colorectal cancer
por: Rattner, Jodi I., et al.
Publicado: (2023) -
Fc‐gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer
por: Shepshelovich, Daniel, et al.
Publicado: (2018) -
A strategy for early detection of response to chemotherapy drugs based on treatment-related changes in the metabolome
por: Amin, Shahil, et al.
Publicado: (2019) -
Monitoring for Response to Antineoplastic Drugs: The Potential of a Metabolomic Approach
por: Rattner, Jodi, et al.
Publicado: (2017) -
Identification of prognostic inflammatory factors in colorectal liver metastases
por: Hamilton, Trevor D, et al.
Publicado: (2014)